These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 20817595)

  • 41. [Restless legs syndrome in kidney patients].
    Cavallini L; Impedovo A; Abaterusso C; Loschiavo C; Lupo A
    G Ital Nefrol; 2010; 27(1):37-46. PubMed ID: 20191459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early manifestations of restless legs syndrome in childhood and adolescence.
    Picchietti DL; Stevens HE
    Sleep Med; 2008 Oct; 9(7):770-81. PubMed ID: 18024165
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Challenging issues: sleep-wake, augmentation and quality of life.
    Partinen M
    Sleep Med; 2007 Aug; 8 Suppl 2():S19-24. PubMed ID: 17562383
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Restless legs syndrome: a common disorder in patients with rheumatologic conditions.
    Hening WA; Caivano CK
    Semin Arthritis Rheum; 2008 Aug; 38(1):55-62. PubMed ID: 17977584
    [TBL] [Abstract][Full Text] [Related]  

  • 45. RESTLESS LEGS SYNDROME AND INSOMNIA FREQUENCY IN PATIENTS WITH PSORIASIS.
    Güler S; Tekatas A; Arican O; Kaplan OS; Dogru Y
    Ideggyogy Sz; 2015 Sep; 68(9-10):331-6. PubMed ID: 26665495
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels.
    Frauscher B; Gschliesser V; Brandauer E; El-Demerdash E; Kaneider M; Rücker L; Poewe W; Högl B
    Sleep Med; 2009 Jun; 10(6):611-5. PubMed ID: 19200780
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Investigational approaches to therapies for restless legs syndrome.
    de Biase S; Merlino G; Lorenzut S; Valente M; Gigli GL
    Expert Opin Investig Drugs; 2014 Jun; 23(6):847-56. PubMed ID: 24708072
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of impact of insomnia on depression and quality of life in restless legs syndrome/Willis-Ekbom disease and primary insomnia patients.
    Song ML; Oldham MA; Park KM; Lee ES; Lee HB; Cho YW
    Sleep Med; 2015 Nov; 16(11):1403-1408. PubMed ID: 26498243
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Restless Legs Syndrome/Willis-Ekbom Disease Morbidity: Burden, Quality of Life, Cardiovascular Aspects, and Sleep.
    Stevens MS
    Sleep Med Clin; 2015 Sep; 10(3):369-73, xv-xvi. PubMed ID: 26329447
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic advances in restless legs syndrome (RLS).
    Högl B; Comella C
    Mov Disord; 2015 Sep; 30(11):1574-9. PubMed ID: 26371624
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Health-related quality of life and economic burden in patients with restless legs syndrome.
    Reese JP; Stiasny-Kolster K; Oertel WH; Dodel RC
    Expert Rev Pharmacoecon Outcomes Res; 2007 Oct; 7(5):503-21. PubMed ID: 20528395
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Frequent difficulties in the treatment of restless legs syndrome - case report and literature review.
    Narowska D; Bożek M; Krysiak K; Antczak J; Holka-Pokorska J; Jernajczyk W; Wichniak A
    Psychiatr Pol; 2015; 49(5):921-30. PubMed ID: 26688843
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gabapentin enacarbil (XP13512/GSK1838262) as an alternative treatment to dopaminergic agents for restless legs syndrome.
    Imamura S; Kushida C
    Expert Opin Pharmacother; 2010 Aug; 11(11):1925-32. PubMed ID: 20629607
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Restless Legs Syndrome in Patients With Chronic Kidney Disease.
    Novak M; Winkelman JW; Unruh M
    Semin Nephrol; 2015 Jul; 35(4):347-58. PubMed ID: 26355253
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term management issues in restless legs syndrome.
    Chokroverty S
    Mov Disord; 2011 Jul; 26(8):1378-85. PubMed ID: 21538518
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The psychopharmacological management of RLS in psychiatric conditions: a review of the literature.
    Cuellar NG
    J Am Psychiatr Nurses Assoc; 2012; 18(4):214-25. PubMed ID: 22529225
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Management of restless legs syndrome].
    Haba-Rubio J; Krieger J
    Presse Med; 2010 May; 39(5):571-8. PubMed ID: 20303704
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study.
    Cornelius JR; Tippmann-Peikert M; Slocumb NL; Frerichs CF; Silber MH
    Sleep; 2010 Jan; 33(1):81-7. PubMed ID: 20120624
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of restless legs syndrome.
    Comella CL
    Neurotherapeutics; 2014 Jan; 11(1):177-87. PubMed ID: 24363103
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome.
    Dang D; Cunnington D; Swieca J
    Clin Neuropharmacol; 2011; 34(2):66-70. PubMed ID: 21412200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.